The Switzerland-headquartered Lonstroff AG is one of the world experts in the development and manufacturing of innovative elastomers for injectable medicines. Our vision is to reinforce our positions of a main credible challenger for rubber component solutions in the Global Injectable Pharma Market by bringing flexibility, service and reliability to our customers and the patients they serve. With 300 team members, three plants in Switzerland and Slovenia and one Research Center in Switzerland, Lonstroff provides long lasting expertise in pure rubber formulations and development. Lonstroff provides solutions for the High Demanding Pharmaceutical and Medical industry, including standard innovative products and development of custom solutions. The product portfolio includes a standard range of Vials Stoppers and Prefilled Syringe components, coated or not coated, available in Ready to Sterilize or Ready to Use solutions. If you need a fast and qualified product development, flexible and reliable supply, high quality of products and services, Lonstroff is the right company to rely upon.
Looking for a particular Lonstroff AG employee's phone or email?
The Lonstroff AG annual revenue was $7.7 million in 2026.
Nicolas Flexas is the CEO of Lonstroff AG.
43 people are employed at Lonstroff AG.
Lonstroff AG is based in Merenschwand, Aargau.
The NAICS codes for Lonstroff AG are [3122, 32, 31, 33, 326, 312].
The SIC codes for Lonstroff AG are [306, 30].